Nautilus Biotechnology Inc
NASDAQ:NAUT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Sonic Automotive Inc
NYSE:SAH
|
US |
|
N
|
Nagpur Power and Industries Ltd
BSE:532362
|
IN |
Nautilus Biotechnology Inc
Total Current Liabilities
Nautilus Biotechnology Inc
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Nautilus Biotechnology Inc
NASDAQ:NAUT
|
Total Current Liabilities
$8m
|
CAGR 3-Years
5%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Total Current Liabilities
$15.2B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
8%
|
CAGR 10-Years
14%
|
|
|
Danaher Corp
NYSE:DHR
|
Total Current Liabilities
$6.8B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
1%
|
|
|
Waters Corp
NYSE:WAT
|
Total Current Liabilities
$1.2B
|
CAGR 3-Years
16%
|
CAGR 5-Years
9%
|
CAGR 10-Years
8%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Total Current Liabilities
$2.2B
|
CAGR 3-Years
5%
|
CAGR 5-Years
6%
|
CAGR 10-Years
9%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Total Current Liabilities
$8.3B
|
CAGR 3-Years
14%
|
CAGR 5-Years
13%
|
CAGR 10-Years
18%
|
|
Nautilus Biotechnology Inc
Glance View
Nautilus Biotechnology, Inc. operates as a life sciences company. The company is headquartered in Seattle, Washington and currently employs 113 full-time employees. The company went IPO on 2020-08-07. The firm is engaged in creating a platform technology for quantifying and unlocking the complexity of the human proteome. The firm focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Its platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The firm is developing a prototype of a single-molecule instrument, Proteomic Analysis System. The Company’s Proteomic Analysis Platform leverages a nanofabricated, single-molecule protein array, multi-cycle imaging, and machine learning analysis to identify and measure the proteome with sensitivity and scale.
See Also
What is Nautilus Biotechnology Inc's Total Current Liabilities?
Total Current Liabilities
8m
USD
Based on the financial report for Dec 31, 2025, Nautilus Biotechnology Inc's Total Current Liabilities amounts to 8m USD.
What is Nautilus Biotechnology Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
22%
Over the last year, the Total Current Liabilities growth was 4%. The average annual Total Current Liabilities growth rates for Nautilus Biotechnology Inc have been 5% over the past three years , 22% over the past five years .
